Immunovant, Inc. - 8-K Filing
Immunovant reported Q4 FY26 financial results with $902.1 million in cash as of March 31, 2026, and a net loss of $147.9 million ($0.73 per share) for the quarter compared to $106.4 million ($0.64 per share) in Q4 FY25. The company provided preliminary data from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, showing 72.7% ACR20 response rates at Week 16. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $IMVT